Brought to you by 
Takeda and AstraZeneca develop MEDI1341 for Parkinson's
29 Aug 2017
Executive Summary
AstraZeneca PLC and Takeda Pharmaceutical Co. Ltd. will jointly develop and sell AZ’s Parkinson’s disease candidate MEDI1341. The project is slated to enter Phase I later this year.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda and AstraZeneca develop MEDI1341 for Parkinson's
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice